Synergistic Neuroprotection by a PAF Antagonist Plus a Docosanoid in Experimental Ischemic Stroke: Dose-Response and Therapeutic Window

OBJECTIVE: We tested the hypothesis that blocking pro-inflammatory platelet-activating factor receptor (PAFR) with LAU-0901 (LAU) plus administering a selected docosanoid, aspirin-triggered neuroprotectin D1 (AT-NPD1), which activates cell-survival pathways after middle cerebral artery occlusion (MC...

Descripción completa

Detalles Bibliográficos
Autores principales: Reid, Madigan M., Obenaus, Andre, Mukherjee, Pranab K., Khoutorova, Larissa, Roque, Cassia R., Petasis, Nicos A., Oria, Reinaldo B., Belayev, Ludmila, Bazan, Nicolas G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9976619/
https://www.ncbi.nlm.nih.gov/pubmed/35717719
http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2022.106585

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9976619/
https://www.ncbi.nlm.nih.gov/pubmed/35717719
http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2022.106585

Ejemplares similares